HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Vicente E Torres Selected Research

Vasopressin Receptors (Arginine Vasopressin Receptor)

4/2015Novel therapeutic approaches to autosomal dominant polycystic kidney disease.
2/2015Effects of hydration in rats and mice with polycystic kidney disease.
1/2015Vasopressin receptor antagonists, heart failure, and polycystic kidney disease.
8/2014The cleaved cytoplasmic tail of polycystin-1 regulates Src-dependent STAT3 activation.
10/2011Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience.
8/2011Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease.
5/2011Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.
7/2008Role of vasopressin antagonists.
5/2008Vasopressin antagonists in polycystic kidney disease.
1/2008Vasopressin directly regulates cyst growth in polycystic kidney disease.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Vicente E Torres Research Topics

Disease

52Autosomal Dominant Polycystic Kidney (ADPKD)
11/2015 - 01/2003
28Cysts
01/2015 - 11/2003
26Polycystic Kidney Diseases (Polycystic Kidney Disease)
08/2015 - 11/2003
10Autosomal Recessive Polycystic Kidney (Polycystic Kidney Disease, Infantile, Type I)
03/2014 - 10/2003
9Hypertension (High Blood Pressure)
01/2015 - 08/2003
6Kidney Diseases (Kidney Disease)
01/2015 - 05/2008
5Fibrosis (Cirrhosis)
11/2015 - 11/2003
5Disease Progression
03/2014 - 03/2007
5Liver Diseases (Liver Disease)
07/2013 - 11/2004
3Heart Failure
11/2015 - 05/2013
3Inflammation
08/2015 - 02/2013
3Chronic Kidney Failure (Chronic Renal Failure)
01/2015 - 05/2002
3Hypotension (Low Blood Pressure)
01/2015 - 03/2012
3Pain (Aches)
12/2014 - 06/2010
2Hepatomegaly
11/2014 - 07/2009
2Encephalocele (Encephalocele, Frontal)
06/2007 - 02/2006
2Polydactyly (Polydactylism)
06/2007 - 02/2006
1Drug-Induced Liver Injury
11/2015
1Hyponatremia
11/2015
1Hypertrophy
01/2015
1Splenomegaly
01/2015
1Hypersplenism (Anemia, Splenic)
01/2015
1Hydrocephalus (Hydrocephaly)
10/2014
1Dilated Cardiomyopathy (Cardiomyopathy, Congestive)
05/2013
1Hyperglycemia
08/2012
1Tuberous Sclerosis (Bourneville's Disease)
01/2012
1Angiomyolipoma
01/2012
1Lymphangioleiomyomatosis (Lymphangiomyomatosis)
01/2012
1Albuminuria
10/2011
1Proteinuria
11/2009

Drug/Important Bio-Agent (IBA)

12tolvaptanFDA Link
11/2015 - 04/2005
12Vasopressins (Vasopressin)IBA
08/2015 - 11/2005
12Vasopressin Receptors (Arginine Vasopressin Receptor)IBA
04/2015 - 01/2004
11Polycystic liver diseaseIBA
08/2015 - 01/2003
10CreatinineIBA
07/2015 - 09/2003
81-dodecylpyridoxal (PLD)IBA
08/2015 - 07/2009
8Proteins (Proteins, Gene)IBA
08/2015 - 09/2003
7CalciumIBA
08/2015 - 01/2006
6Somatostatin (Somatotropin Release-Inhibiting Factor)IBA
04/2015 - 03/2007
6Arginine Vasopressin (Argipressin)IBA
03/2013 - 01/2008
5Octreotide (Sandostatin)FDA LinkGeneric
08/2015 - 03/2007
5Iothalamic Acid (Iotalamic Acid)FDA Link
07/2015 - 09/2003
4Adenosine Monophosphate (AMP)IBA
01/2015 - 06/2009
4AdenosineFDA LinkGeneric
07/2008 - 11/2004
3TEMPOIBA
11/2015 - 05/2011
3Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA
01/2015 - 05/2002
3AngiotensinsIBA
12/2014 - 03/2012
3tebufenozide (Mimic)IBA
06/2014 - 07/2010
3Biological Markers (Surrogate Marker)IBA
03/2013 - 12/2003
3Cyclic AMP (AMP, Cyclic)IBA
08/2011 - 04/2004
3OPC 31260IBA
07/2008 - 04/2005
2pasireotideIBA
01/2015 - 07/2013
2Lisinopril (Prinivil)FDA LinkGeneric
12/2014 - 12/2014
2telmisartan (Micardis)FDA Link
12/2014 - 12/2014
2TRPP Cation ChannelsIBA
07/2013 - 09/2003
2Somatostatin Receptors (Somatostatin Receptor)IBA
07/2013 - 03/2007
2Cystic Fibrosis Transmembrane Conductance Regulator (Protein, CFTR)IBA
01/2010 - 07/2006
2polycystic kidney disease 1 proteinIBA
04/2009 - 02/2009
2SodiumIBA
02/2009 - 01/2007
2Meckel syndrome type 1IBA
06/2007 - 02/2006
2DNA (Deoxyribonucleic Acid)IBA
01/2005 - 06/2003
2EKI 785IBA
11/2004 - 11/2003
2Transforming Growth Factor alpha (TGF-alpha)IBA
11/2004 - 11/2003
2EKB 569IBA
11/2004 - 11/2003
2Epidermal Growth Factor Receptor (EGF Receptor)IBA
11/2004 - 11/2003
2Epidermal Growth Factor (EGF)IBA
11/2004 - 11/2003
1Angiotensin Receptors (Angiotensin II Receptor)IBA
01/2015
1adenylyl cyclase 6IBA
01/2015
1Dihydrotachysterol (AT 10)IBA
01/2015
1AldosteroneIBA
12/2014
1RNA (Ribonucleic Acid)IBA
10/2014
1STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)IBA
08/2014
1matrigelIBA
03/2014
1lanreotide (Somatuline)FDA Link
03/2014
1Nonsense Codon (Nonsense Mutation)IBA
02/2014
1SASIBA
08/2013
1tolcapone (Tasmar)FDA Link
08/2013
1PeptidesIBA
01/2013
1SecretinFDA Link
10/2012
1lipoarabinomannan (LAM)IBA
01/2012
1Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA
10/2011
1Angiotensin Receptor AntagonistsIBA
10/2011
1HDL CholesterolIBA
03/2011
1beta CateninIBA
09/2010
1Nitric Oxide (Nitrogen Monoxide)FDA Link
07/2010
1Messenger RNA (mRNA)IBA
01/2010
1A 7 (A-7)IBA
01/2010
1Protein Isoforms (Isoforms)IBA
01/2010
1pioglitazone (Actos)FDA Link
01/2010
1diethylstilbestrol monophosphate (PDES)IBA
01/2010
1rosiglitazone (Avandia)FDA Link
01/2010
1HormonesIBA
06/2009
1GadoliniumIBA
04/2009

Therapy/Procedure

2Renal Replacement Therapy (Therapies, Renal Replacement)
07/2015 - 01/2015
1Investigational Therapies (Experimental Therapy)
02/2013
1Kidney Transplantation
08/2012
1Transplantation (Transplant Recipients)
08/2012
1Organ Transplantation
01/2010
1Hepatectomy
07/2009
1Liver Transplantation
07/2009